Long-term safety study of lecanemab for Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study collects real-world safety information from people taking the Alzheimer's drug LEQEMBI (also known as lecanemab). It helps doctors understand how well the medicine works outside of clinical trials and what side effects may occur.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been prescribed LEQEMBI and be enrolled in the controlled access program.
- You cannot be taking part in another clinical trial for mild cognitive impairment or Alzheimer's disease.
- You must not have previously taken any anti-amyloid antibody medicine (including lecanemab) for Alzheimer's disease.
- You (or your legal representative) must provide written consent to participate and allow use of your health information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment (X/T plus X-EC) for people with Alzheimer's who are already taking Leqembi (lecanemab). It aims to see if the new drug is safe and well-tolerated.
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
This study collects information from people in Canada who have Alzheimer's disease and are prescribed the drug lecanemab (LEQEMBI). It helps doctors learn more about the drug's safety and effects in real-world use.
This study follows people with Alzheimer's who are already taking Leqembi (lecanemab) after being in the JOY-ALZ study. It collects medical information to check how the treatment works in real-world use.
This study tests whether a drug called leronlimab is safe and can reduce inflammation in the brains of people with mild-to-moderate Alzheimer's disease or memory problems. Researchers will use special brain scans to see if the drug affects inflammation.
This study tests whether adding a new drug called lencanizumab to standard Alzheimer's medications can help slow memory loss in people with early Alzheimer's. It's an observational study, meaning you'll receive the treatment as part of your regular care, and researchers will track your progress.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.